CN103721266A - In-situ gelation injection containing avermectin medicine/hydrogenated castor oil - Google Patents
In-situ gelation injection containing avermectin medicine/hydrogenated castor oil Download PDFInfo
- Publication number
- CN103721266A CN103721266A CN201410003912.4A CN201410003912A CN103721266A CN 103721266 A CN103721266 A CN 103721266A CN 201410003912 A CN201410003912 A CN 201410003912A CN 103721266 A CN103721266 A CN 103721266A
- Authority
- CN
- China
- Prior art keywords
- injection
- medicine
- castor oil
- avermectins
- carrying microgranule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 238000002347 injection Methods 0.000 title claims abstract description 44
- 239000007924 injection Substances 0.000 title claims abstract description 44
- 239000005660 Abamectin Substances 0.000 title claims abstract description 30
- 238000011065 in-situ storage Methods 0.000 title claims abstract description 16
- 239000004359 castor oil Substances 0.000 title claims abstract description 15
- 235000019438 castor oil Nutrition 0.000 title claims abstract description 15
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 title claims abstract description 15
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 title abstract description 4
- 238000001879 gelation Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 239000007864 aqueous solution Substances 0.000 claims abstract description 11
- 239000002245 particle Substances 0.000 claims abstract description 11
- 239000004531 microgranule Substances 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000008215 water for injection Substances 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 4
- 239000000084 colloidal system Substances 0.000 claims description 4
- 229920001993 poloxamer 188 Polymers 0.000 claims description 4
- 229940044519 poloxamer 188 Drugs 0.000 claims description 4
- 239000004576 sand Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- -1 hydroxypropyl Chemical group 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims 1
- 241001494479 Pecora Species 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 241000283690 Bos taurus Species 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000002427 irreversible effect Effects 0.000 abstract description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 230000000857 drug effect Effects 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 229920001992 poloxamer 407 Polymers 0.000 abstract 1
- 229940044476 poloxamer 407 Drugs 0.000 abstract 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 13
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 13
- 229960002418 ivermectin Drugs 0.000 description 13
- 229930192734 Avilamycin Natural products 0.000 description 7
- 239000004190 Avilamycin Substances 0.000 description 7
- XIRGHRXBGGPPKY-OTPQUNEMSA-N [(2r,3s,4r,6s)-6-[(2'r,3's,3ar,4r,4'r,6s,7ar)-6-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4s,5s,6s)-6-[(2r,3as,3'ar,6'r,7r,7's,7ar,7'ar)-7'-acetyl-7'-hydroxy-6'-methyl-7-(2-methylpropanoyloxy)spiro[4,6,7,7a-tetrahydro-3ah-[1,3]dioxolo[4,5-c]pyran-2,4'-6,7a-dihydro-3ah- Chemical compound O([C@H]1[C@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@H](O)CC2(O[C@]3(C)C[C@@H](O[C@H](C)[C@H]3O2)O[C@H]2[C@@H](OC)[C@@H](C)O[C@H]([C@@H]2O)O[C@H]2[C@H](O)[C@H](OC)[C@H](OC3[C@@H]([C@@H]4O[C@]5(O[C@H]4CO3)[C@@H]3OCO[C@H]3[C@@](O)([C@@H](C)O5)C(C)=O)OC(=O)C(C)C)O[C@@H]2COC)O[C@@H]1C)C(=O)C1=C(C)C(Cl)=C(O)C(Cl)=C1OC XIRGHRXBGGPPKY-OTPQUNEMSA-N 0.000 description 7
- 229960005185 avilamycin Drugs 0.000 description 7
- 235000019379 avilamycin Nutrition 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 description 4
- 229960002346 eprinomectin Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 3
- 229960003997 doramectin Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- CKVMAPHTVCTEMM-ALPQRHTBSA-N milbemycin oxime Chemical compound O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\2)O)C[C@H]4C1.C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\1)O)C[C@H]4C2 CKVMAPHTVCTEMM-ALPQRHTBSA-N 0.000 description 2
- 229940099245 milbemycin oxime Drugs 0.000 description 2
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 description 2
- 229960004816 moxidectin Drugs 0.000 description 2
- 239000005645 nematicide Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- JZZIHCLFHIXETF-UHFFFAOYSA-N dimethylsilicon Chemical compound C[Si]C JZZIHCLFHIXETF-UHFFFAOYSA-N 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to an in-situ gelation injection containing avermectin medicine/hydrogenated castor oil drug-loading particles. The injection is prepared by forming drug-loading particles through avermectin medicines and hydrogenated castor oil and suspending the particles in 18-22 percent poloxamer 407 aqueous solution. The injection is simple in preparation process and uniform in release, realizes one-step administration and is used for preventing and treating nematodosis and ectozoic parasite diseases of pigs, cattle and sheep, the effective rate is 95 percent or higher, and the drug effect duration can be 60 days or longer. The injection is high in biocompatibility and does not have irreversible damage to tissues on an injection part, and the used controlled release carrier can be degraded and excreted.
Description
Technical field
The invention belongs to veterinary drug preparation technology of preparing, be specifically related to Avermectins medicine and castor oil hydrogenated (hereinafter to be referred as HCO) to be prepared into medicine carrying microgranule, medicine carrying microgranule is suspended in poloxamer188 (hereinafter to be referred as P407) aqueous solution, and preparation is containing the in-situ gelling injection of Avermectins medicine.
Background technology
Avermectins medicine comprises: ivermectin Ivermectin, avilamycin Avermectin, Eprinomectin Eprinomectin, doractin Doramectin, milbemycin oxime Milbemycin Oxime, moxidectin Moxidectin.These Avermectins medicines are mainly used in preventing and treating nematicide and the epizootic disease of the animals such as pig, cattle, sheep at veterinary clinic, their " character, pharmacology and purposes " etc. are < < veterinary drug handbook > > (Zhu Mozhong chief editor, Chemical Industry Press, July in 2002 the 1st edition, 167-174 page) all on the books and describe and in open source literature.Containing the commercially available injection of Avermectins medicine, majority is to be solution type preparation prepared by solvent with organic solvent (as 1,2-PD, N-Methyl pyrrolidone, formal glycerine etc.) or the grease compounds of synthetic; The disclosed injection containing Avermectins medicine of document or patent has solution type preparation, suspension type preparation, Emulsion, have containing microsphere or microcapsule or containing the long-acting injection of different slow-released carriers (as polyvinylpyrrolidone, polylactic acid, PLGA, Sucrose acetoisobutyrate, castor oil hydrogenated, Semen Ricini wet goods).The long-acting injection of containing hydrogenated Oleum Ricini mainly contains: castor oil hydrogenated and Avermectins medicine are prepared into solid dispersion, suspend in water or the complex media of water and 1,2-PD in, or be suspended in dimethyl-silicon wet goods oil medium; Also have castor oil hydrogenated is dissolved in and in oil medium, prepares slow releasing injection.
Injection of the present invention and technology of preparing thereof are different from published injection and technology of preparing thereof containing Avermectins medicine, feature of the present invention is: Avermectins medicine/HCO medicine carrying microgranule is suspended in the P407 aqueous solution of 18-22%, be prepared into the in-situ gelling injection containing Avermectins medicine/HCO medicine carrying microgranule, after this preparation injects in animal body, under body temperature effect, P407 is converted into gel by colloidal sol, Avermectins medicine/HCO medicine carrying microgranule is wrapped in by gel lump, medicine need slowly decompose just and can complete dispose procedure with the slow dissolving of gel and HCO.Therefore, this preparation is different from the simple in-situ gelling injection containing P407, is also different from the simple slow releasing injection containing HCO solid dispersion.
This process for preparation of injection is simple, and release is even, and single administration reaches 95% or higher for preventing and treating pig, cattle, sheep nematicide and ectoparasite disease effective percentage, effectively sustainable 60 days of drug release time or longer.This injection good biocompatibility, to the tissue of injection site without irreversible damage, slow-released carrier degradable and excretion used.
Summary of the invention
1. preparation forms:
This preparation comprises Avermectins medicine, P407, HCO and water; HCO and Avermectins medicine are prepared to medicine carrying microgranule, with medicine carrying microgranule state, are suspended in P407 aqueous solution, are prepared into in-situ gelling injection.
In every liter of injection, containing Avermectins medicine/HCO medicine carrying microgranule 50-150g, P407180-220g, water for injection adds to 1 liter; In medicine carrying microgranule, the weight ratio of Avermectins medicine and HCO is 1: 0.5-1.
In above-described every liter of injection, can also add hydroxypropyl emthylcellulose (HPMC) 10-30g.
In above-described every liter of injection, can also add 5-10g PLURONICS F87 (P188).
2. preparation method:
(1) by HCO and Avermectins medicine in low boiling point organic solvent (low boiling point organic solvent comprises: methanol, ethanol, ethyl acetate, acetone, chloroform), reflux is treated to dissolve completely, do not stopping under stirring, removal of solvent under reduced pressure, obtain solids, solids is pulverized, crossed 40 mesh sieves, obtain Avermectins medicine/HCO medicine carrying microgranule.
(2) will be about medicine carrying microgranule weight 1.5-2 P407 aqueous solution doubly (containing P407 approximately 10%; weight/volume) mix with medicine carrying microgranule; crossing high-shear homogenizing machine (15000-17000rpm) homogenizes; with colloid mill, be ground to particle diameter afterwards and be less than 80 μ m; with sand mill, be ground to particle diameter again and be less than 30 μ m; add residue composition; after homogenizing with homogenizer; degassed under 5-15 ℃, negative pressure 0.06-0.08mpa condition, must be containing the in-situ gelling injection of Avermectins medicine/HCO medicine carrying microgranule.
The specific embodiment
Embodiment 1,10% avilamycin in-situ gelling injection preparation
Preparation forms: every liter of preparation adds to 1 liter containing avilamycin/HCO (weight ratio is 1: 0.5) medicine carrying microgranule 150g, P407180g, water for injection.
Preparation method: (1) by castor oil hydrogenated in 90-95 ℃ of thawing, be cooled to 70 ℃ of left and right, add avilamycin and appropriate ethanol, reflux avilamycin is dissolved completely, afterwards at stirring condition borehole cooling to 40-55 ℃, distilling under reduced pressure, Ex-all ethanol, obtains solids, pulverizes, cross 40 mesh sieves, obtain avilamycin/HCO medicine carrying microgranule.(2) the 10%P407 aqueous solution with appropriate (being about the 1.5-2 of medicine carrying microgranule amount doubly) by medicine carrying microgranule, cross high-shear homogenizing machine and shear 3-5 time, with colloid mill, be ground to particle diameter afterwards and be less than 80 μ m, then with sand mill, be ground to particle diameter and be less than 20 μ m, obtain dense thick suspension.(3) in suspension, add remaining P407 aqueous solution, after homogenizing with homogenizer, degassed under 5-15 ℃, negative pressure 0.06-0.08mpa condition, must be containing the in-situ gelling injection of avilamycin/HCO medicine carrying microgranule.
Embodiment 2,7% ivermectin in-situ gelling injection preparation
Ivermectin/HCO (weight ratio is 1: 1) medicine carrying microgranule 140g, P407180g, water for injection add to 1 liter.
Preparation method: (1) by castor oil hydrogenated in 90-95 ℃ of thawing, be cooled to 70C left and right, add ivermectin and the suitable ethanol of ivermectin triplication, reflux ivermectin is dissolved completely, afterwards at stirring condition borehole cooling to 40-55 ℃, distilling under reduced pressure, Ex-all ethanol, obtains solids, pulverizes, cross 40 mesh sieves, obtain ivermectin/HCO medicine carrying microgranule.(2) the 10%P407 aqueous solution with appropriate (being about the 1.5-2 of medicine carrying microgranule amount doubly) by medicine carrying microgranule, cross high-shear homogenizing machine and shear 3-5 time, with colloid mill, be ground to particle diameter afterwards and be less than 80 μ m, then with sand mill, be ground to particle diameter and be less than 20 μ m, obtain dense thick suspension.(3) in suspension, add remaining P407 aqueous solution, after homogenizing with homogenizer, degassed under 5-15 ℃, negative pressure 0.06-0.08mpa condition, must be containing the in-situ gelling injection of ivermectin/HCO medicine carrying microgranule.
Embodiment 3,5% doramectin in-situ gelling injection preparation
Doramectin/HCO (weight ratio is 1: 0.8) medicine carrying microgranule 90g, P407200g, water for injection add to 1 liter.
Embodiment 4,7.5% Eprinomectin injection
Eprinomectin/HCO (weight ratio is 1: 1) medicine carrying microgranule 150g, P407180g, P18810g, HPMC22g, water for injection adds to 1 liter.
Embodiment 5,5% ivermectin in-situ gelling injection preparation
Ivermectin/HCO (weight ratio is 1: 1) medicine carrying microgranule 50g, ivermectin/HCO (weight ratio is 1: 0.5) medicine carrying microgranule 37.5g, P407180g, P18810g, HPMC20g, glycerol 65g, water for injection adds to 1 liter.
Injection described in above embodiment 3 to embodiment 5, preparation method is with embodiment 1.
Embodiment 6, the embodiment 5 preparations blood drug level in sheep body detects
Experimental animal grouping and result of the test: select 9 of healthy sheep, be divided into 3 groups, every group 3, cervical region subcutaneous injection embodiment 5 preparations, dosage is respectively 0.5mg/kg b.w. (A group), 0.8mg/kg b.w. (B group), 1.2mg/kg b.w. (C group), blood sampling on time, separated plasma, and after the plasma sample of same time is on the same group mixed with acetonitrile extraction, through centrifugal, purify (C
18post), the process such as concentrated, derivatization, make detection sample, adopt ivermectin content in HPLC (fluorescence detector) working sample.
Testing result is as shown in the table:
More than in table, numerical value is the meansigma methods of every group of 3 sheep blood plasma drug level.
Claims (5)
1. containing a long-acting injection for Avermectins medicine, it is characterized in that Avermectins medicine and castor oil hydrogenated combination, with medicine carrying microgranule state, be suspended in the aqueous solution that comprises poloxamer188, be prepared into in-situ gelling injection.
2. by injection claimed in claim 1, it is characterized in that every liter of injection comprises following component:
Weight ratio is 1: Avermectins medicine/castor oil hydrogenated medicine carrying microgranule 50-150g of 0.5-1
Poloxamer188 180-220g
Water for injection adds to 1 liter.
3. by injection claimed in claim 2, it is characterized in that preparation method is as follows:
A puts into castor oil hydrogenated and Avermectins medicine to be equivalent in ethanol or acetone or ethyl acetate that Avermectins medicine 2.5-4 doubly measures, be heated to 80 ℃ of left and right, treat to dissolve completely, under agitation, distilling under reduced pressure is except desolventizing, obtain solids and pulverize, cross 40 mesh sieves, obtain Avermectins medicine/castor oil hydrogenated medicine carrying microgranule;
B mixes the 10% poloxamer188 aqueous solution that is equivalent to medicine carrying microgranule 1.5-2 times weight with medicine carrying microgranule; cross high-shear homogenizing machine; shear 3-5 time; with colloid mill, be ground to particle diameter and be less than 80 μ m; with sand mill, grind particle diameter again and be less than 30 μ m, add residue composition, after homogenizing with homogenizer; degassed under 5-15 ℃, negative pressure 0.06-0.08mpa condition, make the in-situ gelling injection containing Avermectins medicine/castor oil hydrogenated medicine carrying microgranule.
4. by the injection described in claim 2-3 any one, it is characterized in that can also adding 10-30g hydroxypropyl emthylcellulose in every liter of injection.
5. by the injection described in claim 2-3 any one, it is characterized in that can also adding 5-30g PLURONICS F87 in every liter of injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410003912.4A CN103721266A (en) | 2014-01-06 | 2014-01-06 | In-situ gelation injection containing avermectin medicine/hydrogenated castor oil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410003912.4A CN103721266A (en) | 2014-01-06 | 2014-01-06 | In-situ gelation injection containing avermectin medicine/hydrogenated castor oil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103721266A true CN103721266A (en) | 2014-04-16 |
Family
ID=50445724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410003912.4A Pending CN103721266A (en) | 2014-01-06 | 2014-01-06 | In-situ gelation injection containing avermectin medicine/hydrogenated castor oil |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103721266A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107811967A (en) * | 2016-09-09 | 2018-03-20 | 中国疾病预防控制中心寄生虫病预防控制所 | Anti-parasite medicine in-situ solidification sustained-release injector and preparation method thereof |
| CN110721152A (en) * | 2018-12-29 | 2020-01-24 | 瑞普（天津）生物药业有限公司 | Sustained-release composition for treating animal skin parasite and fungus infection |
| CN113209012A (en) * | 2021-06-04 | 2021-08-06 | 湖南伟达科技有限公司 | Avermectin transdermal solution and preparation method thereof |
| WO2022254199A1 (en) * | 2021-06-01 | 2022-12-08 | Hovione Scientia Limited | Process to reduce ivermectin particle size |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0535734A1 (en) * | 1991-09-30 | 1993-04-07 | Merck & Co. Inc. | Long acting injectable formulations containing hydrogenated castor oil |
| WO1999051201A1 (en) * | 1998-04-03 | 1999-10-14 | Ashmont Holdings Limited | Sustained release formulation |
| CN1283990A (en) * | 1997-12-03 | 2001-02-14 | 麦克公司 | Long cating injectable formulations contg. hydrogenated castor oil |
| CN1461640A (en) * | 2002-05-31 | 2003-12-17 | 王玉万 | Slow releasing injection contg. antiparasitic medicine |
| CN1565470A (en) * | 2003-07-10 | 2005-01-19 | 王玉万 | Antiparasitic medicine long-acting injection containing |
| CN1572300A (en) * | 2003-05-25 | 2005-02-02 | 王玉万 | Avermectin containing parasite resisitant long-acting injectio |
| CN1572302A (en) * | 2003-05-29 | 2005-02-02 | 王玉万 | Application of avermectin containing parasite resistant pharmaceutical solid dispersion |
| WO2005084688A1 (en) * | 2004-03-04 | 2005-09-15 | Yuwan Wang | An injection power containing vermifuge |
| CN1698637A (en) * | 2004-05-17 | 2005-11-23 | 王玉万 | Powder injection of macrolides or N-phenyl pyrazoles deworming drug |
-
2014
- 2014-01-06 CN CN201410003912.4A patent/CN103721266A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0535734A1 (en) * | 1991-09-30 | 1993-04-07 | Merck & Co. Inc. | Long acting injectable formulations containing hydrogenated castor oil |
| CN1283990A (en) * | 1997-12-03 | 2001-02-14 | 麦克公司 | Long cating injectable formulations contg. hydrogenated castor oil |
| WO1999051201A1 (en) * | 1998-04-03 | 1999-10-14 | Ashmont Holdings Limited | Sustained release formulation |
| CN1461640A (en) * | 2002-05-31 | 2003-12-17 | 王玉万 | Slow releasing injection contg. antiparasitic medicine |
| CN1572300A (en) * | 2003-05-25 | 2005-02-02 | 王玉万 | Avermectin containing parasite resisitant long-acting injectio |
| CN1572302A (en) * | 2003-05-29 | 2005-02-02 | 王玉万 | Application of avermectin containing parasite resistant pharmaceutical solid dispersion |
| CN1565470A (en) * | 2003-07-10 | 2005-01-19 | 王玉万 | Antiparasitic medicine long-acting injection containing |
| WO2005084688A1 (en) * | 2004-03-04 | 2005-09-15 | Yuwan Wang | An injection power containing vermifuge |
| CN1698637A (en) * | 2004-05-17 | 2005-11-23 | 王玉万 | Powder injection of macrolides or N-phenyl pyrazoles deworming drug |
Non-Patent Citations (1)
| Title |
|---|
| 高存帅等: "注射用泊洛沙姆407温敏型原位凝胶的研究进展", 《中国动物检疫》, vol. 29, no. 5, 31 December 2012 (2012-12-31) * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107811967A (en) * | 2016-09-09 | 2018-03-20 | 中国疾病预防控制中心寄生虫病预防控制所 | Anti-parasite medicine in-situ solidification sustained-release injector and preparation method thereof |
| CN107811967B (en) * | 2016-09-09 | 2021-08-24 | 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) | Antiparasitic in-situ curing slow-release injection and preparation method thereof |
| CN110721152A (en) * | 2018-12-29 | 2020-01-24 | 瑞普（天津）生物药业有限公司 | Sustained-release composition for treating animal skin parasite and fungus infection |
| CN110721152B (en) * | 2018-12-29 | 2022-01-14 | 瑞普（天津）生物药业有限公司 | Sustained-release composition for treating animal skin parasite and fungus infection |
| WO2022254199A1 (en) * | 2021-06-01 | 2022-12-08 | Hovione Scientia Limited | Process to reduce ivermectin particle size |
| CN113209012A (en) * | 2021-06-04 | 2021-08-06 | 湖南伟达科技有限公司 | Avermectin transdermal solution and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103721266A (en) | In-situ gelation injection containing avermectin medicine/hydrogenated castor oil | |
| CN107811967A (en) | Anti-parasite medicine in-situ solidification sustained-release injector and preparation method thereof | |
| CN106063783A (en) | A kind of Progesterone slow-releasing microcapsule preparation and preparation method thereof | |
| CN105012236A (en) | Long-acting non-water-carrier injection liquid and preparing method thereof | |
| JP5419169B2 (en) | Sustained release pharmaceutical composition comprising fine particles | |
| CN102423300A (en) | Acetyl amino abamectin sustained-release microsphere and preparation method as well as sustained-release microsphere injection | |
| CA3137819C (en) | Sustained-release microparticles containing deslorelin, and preparation method therefor | |
| CN103720652B (en) | Prepare containing Avermectins medicine injection with poloxamer and oil medium | |
| JP2017524035A (en) | Method for producing drug-containing sustained-release fine particles | |
| JP2021534155A (en) | Sustained release injection containing deslorerin and its manufacturing method | |
| CN101590055A (en) | A kind of water soluble decoquinate and preparation method thereof | |
| CN103705452B (en) | Containing the antibacterials injection of poloxamer188 and oil medium | |
| CN102429918A (en) | Pharmaceutical composition containing florfenicol and tea saponin and preparation method thereof | |
| Bazybek et al. | Advances in encapsulating gonadotropin-releasing hormone agonists for controlled release: a review | |
| CN105343031B (en) | A kind of ivermectin solid lipid nano granule and preparation method thereof | |
| CN103520119B (en) | The preparation method of imidocard dipropionate long-acting veterinary preparation | |
| CN103830170A (en) | Ivermectin in-vivo gel injection and preparation method thereof | |
| CN103705451A (en) | In-situ gelling injection containing praziquantel/hydrogenated castor oil | |
| CN103721263A (en) | Oil injection containing antibacterial agents/polyethylene glycol drug-loading particles | |
| CN110141580A (en) | A kind of animal povidone iodine and diethylstilbestrol compound suppository and preparation method thereof | |
| CN104095812B (en) | The preparation method of the emulsifiable oily injection containing Avermectins medicine | |
| CN103585131A (en) | Preparation method for ivermectin sustained-release gelatin microcapsule | |
| CN104095815A (en) | Preparation method for tulathromycin emulsifable injection | |
| CN105535933A (en) | Leuprorelin medicinal composition injection type hypodermic implantation agent | |
| CN103705445A (en) | In-situ gelling injection containing mequindox/hydrogenated castor oil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING AGRICHINA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG YUWAN Effective date: 20150106 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100083 HAIDIAN, BEIJING TO: 102206 CHANGPING, BEIJING |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150106 Address after: 102206 Beijing city Changping District Baishan Town East Village profile West Industrial Zone No. 535 Pro Applicant after: BEIJING AGRICHINA PHARMACEUTICAL CO., LTD. Address before: 100083 Beijing Qinghua East Road, No. 17,, 41-5-102 Applicant before: Wang Yuwan |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140416 |